Invivyd (IVVD) Set to Release Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) is projected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.11) per share and revenue of $15.04 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. On average, analysts expect Invivyd to post ($0.51) EPS for the current fiscal year and ($0.43) EPS for the next fiscal year.

Invivyd Stock Down 0.1%

IVVD stock opened at $0.58 on Wednesday. The company has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $1.16. Invivyd has a fifty-two week low of $0.53 and a fifty-two week high of $3.07.

Analysts Set New Price Targets

IVVD has been the topic of a number of research reports. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Monday, September 14th. HC Wainwright restated a “buy” rating on shares of Invivyd in a report on Tuesday, September 29th. Cantor Fitzgerald restated an “overweight” rating on shares of Invivyd in a research report on Thursday, August 27th. Finally, Weiss Ratings upgraded shares of Invivyd from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 8th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Insider Activity

In other news, insider Jill Andersen sold 30,706 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $0.84, for a total value of $25,793.04. Following the completion of the sale, the insider owned 283,774 shares in the company, valued at $238,370.16. This represents a 9.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 228,024 shares of company stock valued at $176,540 in the last ninety days. 12.25% of the stock is owned by corporate insiders.

Invivyd Company Profile

Invivyd, Inc is a biotechnology company focused on developing antibody-based medicines designed to prevent and treat infectious diseases. The company uses its antibody discovery and engineering technologies to create broadly neutralizing antibodies intended to remain effective as viruses evolve.

Invivyd’s lead product is pemivibart, marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration granted pemivibart an Emergency Use Authorization in 2024 for pre-exposure prophylaxis against COVID-19 in certain individuals who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to vaccination.